A Phase 4 interventional study of Methadone and Buprenorphine (BUP) in Opioid Use Disorder, sponsored by Yale University. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Yale University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing methadone in Opioid-Related Disorders — 4 open to participants now, 4 under way, 1 of them phase 3. Methadone · Opioid-Related Disorders.
Among the 19 studies testing methadone in Opioid-Related Disorders, this one has the largest planned enrollment, is the only one that started in 2024, is one of 5 in phase 4, and was the 17th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →4 of the 19 studies testing methadone in Opioid-Related Disorders are open now, in 2 countries. Recruiting first, the newest first:
Ashish P Thakrar, MD MS · Sites in United States
Ages 18+
University of Maryland, Baltimore · Sites in United States
Ages 18–100
Pouya Azar · Sites in Canada
Ages 19+
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 5
First in 1995; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 68 across the 19 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 19 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
106 studies in Opioid-Related Disorders by Yale University: 20 open now, 24 under way, 1 of them phase 3. Of 75 finished, 27 (36%) have results posted.
Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 11th largest by planned enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2024, is one of 9 in phase 4, reaches primary completion later than 19 of the 23 other live ones, and was the 85th registered.
Yale University’s Opioid-Related Disorders studies by the year they started, since 1988.
2 of the studies testing methadone in Opioid-Related Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05459402Phase 3University of Maryland, BaltimoreDivided or Single Exposure (DOSE) Study | 2027-06-01 |
| NCT07546396Pouya AzarMethadone Rapid Restart | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies testing methadone in Opioid-Related Disorders, from their registry updates:
Among Yale University’s 106 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to compare the effectiveness of office-based methadone with pharmacy administration and/or dispensing to office-based buprenorphine for the treatment of opioid use disorder. This study will also examine factors influencing the implementation of office-based methadone.
This study is a randomized, pragmatic hybrid type 1 effectiveness/implementation multisite (approximately 6 sites) trial to determine whether office-based methadone with pharmacy administration and/or dispensing or buprenorphine (BUP) results in greater treatment retention in approximately 600 patients with opioid use disorder (OUD). This trial will also identify implementation barriers, facilitators and acceptability at the patient, provider and health-systems level for office-based methadone with pharmacy administration and/or dispensing.
An ancillary extended study was added to this trial in January of 2026. A sub-set of current participants that were receiving office based methadone as of day 168 of the parent study will continue to be followed for other pre-specified outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Under special Drug Enforcement Administration (DEA) exception, Clinician prescribes methadone and oral methadone is administered and/or dispensed at a pharmacy which also has an exception to do so. All randomized controlled trial (RCT) participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
Drug: Methadone
Clinician prescribes BUP formulations that are dispensed at a pharmacy or administered in the office (e.g., extended-release formulations). All RCT participants are offered additional behavioral treatments (e.g., individual, group, telehealth, phone-based).
Drug: Buprenorphine (BUP)
Drug: Methadone Possible formulations: 10 and 50 mg tablets
Drug: Buprenorphine (BUP) Possible formulations: A. Buprenorphine, 225 mcg to 24 mg, 225 mcg to 32 mg per day, B. Buprenorphine (Extended release), 300 mg q 28 days (Sublocade), 100 mg q 28 days (Sublocade), 8 mg q 7 days (Brixadi), 16 mg q 7 days (Brixadi), 24 mg q 7 days (Brixadi), 32 mg q 7 days (Brixadi), 64 mg q 28 days (Brixadi), 96 mg q 28 days (Brixadi), 128 mg q 28 days (Brixadi),
Number of days of continuous treatment with site clinician-prescribed methadone or buprenorphine, as randomized, during the 168 days post-randomization among RCT participants.
This measure is based on PDMP data for methadone and non-injectable buprenorphine and EMR data for injectable buprenorphine formulations
Time frame: up to Day 168
Number of self-reported continuous treatment days in any FDA-approved formulation of MOUD treatment during the 168 days post-randomization.
This measure is assessed using the MOUD Calendar Based Recall Recall Instruments.
Time frame: up to Day 168
Number of self-reported continuous treatment days in formal OUD treatment, according to American Society of Addiction Medicine (ASAM) levels of care 1-4, during the 168 days post-randomization.
This measure is assessed using one or more of the following: The Health Services Utilization instrument, a brief structured interview regarding health care utilization (inpatient and outpatient) collecting information on the type and amount of services received, Timeline Followback Medications, MOUD Calendar Based Recall, and Treatment Dates instruments.
Time frame: up to Day 168
Total number of days receiving any FDA-approved MOUD formulation during the 168 days post-randomization.
This measure is assessed using EMR (for injectable MOUD formulations) and PDMP data.
Time frame: up to Day 168
The longest duration of continuous treatment episode with MOUD, as randomized, during the 168 days post randomization.
This measure is based on PDMP and/or EMR data.
Time frame: up to Day 168
Total number of days receiving methadone or buprenorphine, during the 168 days post-randomization.
This measure is assessed using EMR (for injectable MOUD formulations) and PDMP data.
Time frame: up to Day 168
Total number of days of self-reported non-prescribed opioid use during each 28-day assessment period.
This measure is assessed by the Opioid Use Calendar Based Recall instruments.
Time frame: up to Day 168
Total number of days of self-reported non-prescribed stimulant use during each 28-day assessment period.
This measure is assessed by the Timeline Followback instrument.
Time frame: up to Day 168
Total number of days of self-reported non-prescribed benzodiazepine use during each 28-day assessment period.
This measure is assessed by the Timeline Followback instrument.
Time frame: up to Day 168
Urine toxicology
Total number of monthly (28 days) urines negative for non-prescribed opioids during the 168 days post-randomization. Non-prescribed opioids will be determined using the Opioid Use Calendar Based Recall instrument.
Time frame: up to Day 168
Participant satisfaction with MOUD
Proportion of RCT participants who report at the assessment scheduled to be collected on day 28 that the medication they received was at least "Somewhat helpful" on the Satisfaction with MOUD Provider Scale instrument.
Time frame: up to Day 168
Total number of self-reported overdose events per total number of participant days at risk.
The Overdose Calendar Recall instrument collects overdose events.
Time frame: up to Day 168
Total number of self-reported injection drug use related events during each 28-day assessment period.
Assessment of Infectious or Other Complications of Injection Drug Use assess for skin abscesses, ulcers , cellulitis, osteoarticular septic arthritis, osteomyelitis, epidural infection , endovascular, new injection-related viral infections diagnosis of Hepatitis or HIV.
Time frame: Up to Day 168
Mean score Pain measured using Pain, Enjoyment of Life and General Activity (PEG) Scale (PEG-3)
Mean scores on the PEG-3 instrument over time. The PEG-3 instrument is collected every 28 days. The mean score is the average of the three 0-10 rated items. Total score range 0-10. Higher scores indicate worse pain.
Time frame: Up to Day 168
Total number of self-reported days with acute care utilization (ED or hospitalization) during each 28-day assessment period.
The Health Services Utilization instrument is a brief, structured interview regarding health care utilization (inpatient and outpatient) collecting information on the type and amount of services received. This includes ED visits, hospitalizations, primary medical care visits (excluding those for BUP treatment) and self-help sources of support (e.g., NA). Also assessed are receipt of formal and informal addiction and mental health treatment services RCT participants might have received outside the study interventions.
Time frame: Up to Day 168
Total number of behavioral counseling service visits attended per participant during each 28-day assessment period.
Assessed by EMR extraction and the Health Services Utilization.
Time frame: Up to Day 168
Total number of planned prescriber visits attended during each 28-day assessment period.
Assessed by EMR extraction.
Time frame: Up to Day 168
Pharmacist practice fidelity
Assessed by MOUD Visit Checklist completion over time. The MOUD Visit Checklist collects clinical activities that might be performed by a pharmacist at each pharmacy, such as performing medication reconciliation; conducting safety assessments, adverse effects of methadone, recent overdose events, checking the patient's controlled medications prescription status using the PDMP before dispensing methadone; providing patient education/counseling; communicating with the clinician regarding any concern; and administering one methadone dose at the pharmacy and/or dispensing methadone according to the prescription.
Time frame: Up to Day 168
Retention in office-based methadone treatment
Retention will be defined as the number of days of continuous office-based methadone treatment (time to event outcome) staring at day 168. Discontinuation of methadone for the extended study component will be defined as more than a self-reported 30-day gap in receipt of methadone or non-response on two consecutive 60-day assessments. The date of discontinuation will be the end of the last 30-day period with any self-reported office-based methadone treatment. Participants who remain in continuous treatment through the end of the study and will be censored on day of the last 60 day assessment. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Percentage of days covered of self-reported pharmacy dispensed methadone treatment
Percentage of days covered of self-reported pharmacy dispensed methadone treatment (i.e., number of self-reported days covered per total days observed). Only collected in extended study participants.
Time frame: starting at day 168 post enrollment up to 2 years
Total number of self-reported overdose events
To assess overdose events, participants will self-report the number of overdose events in the past 28 days. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Methadone dose
Participants will self-report the most recent daily dose (in milligrams) of methadone prescribed and obtained from the pharmacy. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Days of treatment
Days of treatment will be the count of self-reported number of days the participant self reported taking prescribed methadone. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Treatment Effectiveness Assessment (TEA)
The TEA collects self-report data across four domains: substance use, health, lifestyle, and community. This will be analyzed as a repeated measure of overall numerical score. Total score range 4-40. higher scores mean greater improvement. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Health service utilization
Participants will be asked to report the inpatient and outpatient services they used in the past 28 days. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Health related quality of life
To assess health related quality of life, participants will self-report their general health, physical health, and mental health during the past 28 days. This will be analyzed as a repeated measure of overall numerical score. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Crime and criminal justice involvement
To assess crime and criminal justice, participants will self-report how many days in the past 60 days they have been incarcerated, if they have been in contact with the court, criminal justice system, or probation/parole officer and how many of those days in the past 60 they were incarcerated, in contact with the court, criminal justice system or probation/parole officer. Criminal justice involvement will be defined as the percentage of days of self-reported involvement (i.e., number of self-reported days per total days observed). Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
End of study status
End of study status for participants which includes; office-based methadone treatment at end of study, withdrew consent, deceased, unable to contact, no longer being prescribed methadone from the site. End of study status will be reported by study site Research Associates or Site Clinicians. Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Substance use
To assess substance use, participants will self-report how many of the past 60 days that they used a substance. Monthly substance use obtained through survey assessment at each 60- day assessment. Total number of days of self-reported substance use during each 60 day assessment period (discrete or continuous outcome, repeated measure). Only collected in extended study participants.
Time frame: Starting at day 168 post enrollment up to 2years
Plan to share: Yes — The National Institute on Drug Abuse (NIDA) Data Share web site is an electronic environment that allows data from completed clinical trials to be distributed to investigators and the public in order to promote new research, encourage further analyses, and disseminate information to the community. Secondary analyses produced from data sharing multiply the scientific contribution of the original research. NIH expects and supports the timely release and sharing of final research data from NIH-supported studies for use by other researchers to expedite the translation of research results into knowledge, products and procedures to improve human health.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data sets will be available after (1) the primary paper has been accepted for publication, or (2) the data is locked for more than 18 months, whichever comes first.
Access criteria: Public
Data sharing details ↗ · datashare.nida.nih.gov
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Dec 2028, 54 months after the start.
Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 54 months is above that.
Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone